211 related articles for article (PubMed ID: 22012708)
1. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
[TBL] [Abstract][Full Text] [Related]
2. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
Thompson BW; Miller ST; Rogers ZR; Rees RC; Ware RE; Waclawiw MA; Iyer RV; Casella JF; Luchtman-Jones L; Rana S; Thornburg CD; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik S; Howard TH; Luck L; Wang WC
Pediatr Blood Cancer; 2010 Feb; 54(2):250-5. PubMed ID: 19731330
[TBL] [Abstract][Full Text] [Related]
3. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
Alvarez O; Miller ST; Wang WC; Luo Z; McCarville MB; Schwartz GJ; Thompson B; Howard T; Iyer RV; Rana SR; Rogers ZR; Sarnaik SA; Thornburg CD; Ware RE;
Pediatr Blood Cancer; 2012 Oct; 59(4):668-74. PubMed ID: 22294512
[TBL] [Abstract][Full Text] [Related]
4. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
Lebensburger JD; Miller ST; Howard TH; Casella JF; Brown RC; Lu M; Iyer RV; Sarnaik S; Rogers ZR; Wang WC;
Pediatr Blood Cancer; 2012 Oct; 59(4):675-8. PubMed ID: 22190441
[TBL] [Abstract][Full Text] [Related]
5. Impact of hydroxyurea on clinical events in the BABY HUG trial.
Thornburg CD; Files BA; Luo Z; Miller ST; Kalpatthi R; Iyer R; Seaman P; Lebensburger J; Alvarez O; Thompson B; Ware RE; Wang WC;
Blood; 2012 Nov; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
[TBL] [Abstract][Full Text] [Related]
6. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
8. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
9. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.
Wang WC; Oyeku SO; Luo Z; Boulet SL; Miller ST; Casella JF; Fish B; Thompson BW; Grosse SD;
Pediatrics; 2013 Oct; 132(4):677-83. PubMed ID: 23999955
[TBL] [Abstract][Full Text] [Related]
11. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Ware RE; Dertinger SD
Br J Haematol; 2021 Jul; 194(2):252-266. PubMed ID: 33570176
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and growth in young children with sickle cell disease.
Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B;
Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?
McGann PT; Ware RE
Curr Opin Hematol; 2011 May; 18(3):158-65. PubMed ID: 21372708
[TBL] [Abstract][Full Text] [Related]
14. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
15. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
16. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
17. How I use hydroxyurea to treat young patients with sickle cell anemia.
Ware RE
Blood; 2010 Jul; 115(26):5300-11. PubMed ID: 20223921
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea use among children with sickle cell anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
[TBL] [Abstract][Full Text] [Related]
20. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Flanagan JM; Howard TA; Mortier N; Avlasevich SL; Smeltzer MP; Wu S; Dertinger SD; Ware RE
Mutat Res; 2010 Apr; 698(1-2):38-42. PubMed ID: 20230905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
